Suggested remit: To appraise the clinical and cost effectiveness of fosdenopterin within its marketing authorisation for treating molybdenum cofactor deficiency type A.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
HST Standard
|
| ID number |
6264
|
Provisional Schedule
| Committee meeting |
05 September 2024 |
| Expected publication |
29 January 2025 |
Project Team
| Project lead |
Celia Mayers |
Email enquiries
| External Assessment Group |
Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
| Companies sponsors |
Sentynl Therapeutics (Fosdenopterin) |
| Others |
Birmingham Children’s Hospital NHS Foundation Trust |
| |
Department of Health and Social Care |
| |
NHS England |
| |
Willink Unit, Genetic Medicine, Manchester University Hospitals NHS Foundation Trust |
| Patient carer groups |
Gene People |
| |
Metabolic Support UK |
| Professional groups |
Royal College of Physicians |
| Comparator companies |
None |
| General commentators |
All Wales Inherited Metabolic Disease Service |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
National Institute for Health Research |
|
Date
|
Update
|
|
08 May 2024
|
After receiving the external assessment report, NICE has assessed the evidence submissions and report to decide how this appraisal will progress. This appraisal will continue as a highly specialised technology and progress to technical engagement before preparation for the committee meeting. To accommodate the addition of technical engagement, the committee meeting will now be held on 5 September 2024. |
|
22 November 2023
|
Invitation to participate |
|
30 October 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
30 October 2023
|
Topic selection |
|
30 October 2023
|
Topic selection |
|
30 October 2023
|
In progress |
|
26 September 2023 (14:00)
|
Scoping workshop |
|
26 July 2023 - 23 August 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6264 |
|
15 June 2023
|
In progress. DHSC referral received |
|
20 March 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual